Recursion Pharmaceuticals Inc (RXRX) Stock Analysis

Verdict: WATCH (do not buy)

Heavy cash burn and share dilution overshadow AI-discovery potential, making current 44.3x P/S valuation vulnerable to clinical delay risks.

Investment score: 41/100

Analysis as of 2026-10-07

Is Recursion Pharmaceuticals Inc stock worth reviewing? AI model thesis

The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.

7-factor investment score

Valuation: 35/100 (weight 20%)
Financial Health: 30/100 (weight 15%)
Technical Momentum: 62/100 (weight 15%)
Earnings Quality: 45/100 (weight 15%)
Insider Sentiment: 20/100 (weight 10%)
Analyst Consensus: 60/100 (weight 10%)
Risk-Adjusted Return: 35/100 (weight 15%)

Recursion Pharmaceuticals Inc opportunities and risks

What speaks for RXRX

Genentech/Roche & Bayer Strategic Collaborations

What speaks against RXRX

Severe Cash Burn and Ongoing Shareholder Dilution

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
RXRX	n/a	44.3x	n/a	-46.7%	-945.9%	-14.6%
DYN	n/a	0.0x	n/a	0.0%	0.0%	-17.4%
PGEN	n/a	31.4x	n/a	89.6%	-184.0%	-4.3%
BEAM	n/a	16.6x	n/a	18.9%	-54.7%	-14.4%
CLDX	n/a	18419.9x	n/a	-56850.9%	-268385.7%	-11.7%
IRON	n/a	0.0x	n/a	0.0%	0.0%	-8.3%
Peer median	n/a	16.6x	n/a	0.0%	-54.7%	-11.7%

Frequently asked questions about Recursion Pharmaceuticals Inc (RXRX)

Is RXRX stock a good investment?

The cached TradeMates AI model rates Recursion Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 41/100. The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.

Is RXRX stock a buy?

The TradeMates model verdict for RXRX is WATCH (do not buy) with an investment score of 41/100. Treat this as a model signal to review, not a personal buy recommendation.